Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H20ClF3N2O.ClH |
| Molecular Weight | 433.295 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@]1(CCCCN1)[C@@H](NC(=O)C2=C(Cl)C(=CC=C2)C(F)(F)F)C3=CC=CC=C3
InChI
InChIKey=YGCZZYKACZXKHK-AKXYIILFSA-N
InChI=1S/C20H20ClF3N2O.ClH/c21-17-14(9-6-10-15(17)20(22,23)24)19(27)26-18(13-7-2-1-3-8-13)16-11-4-5-12-25-16;/h1-3,6-10,16,18,25H,4-5,11-12H2,(H,26,27);1H/t16-,18-;/m0./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C20H20ClF3N2O |
| Molecular Weight | 396.834 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | ( + ) |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacological characterization of [³H]CHIBA-3007 binding to glycine transporter 1 in the rat brain. | 2011 |
|
| Inhibition of glycine transporter-1 reduces cue-induced nicotine-seeking, but does not promote extinction of conditioned nicotine cue responding in the rat. | 2013 Sep |
|
| Discovery of 3-Chloro-N-{(S)-[3-(1-ethyl-1H-pyrazol-4-yl)phenyl][(2S)-piperidine-2-yl]methyl}-4-(trifluoromethyl)pyridine-2-carboxamide as a Potent Glycine Transporter 1 Inhibitor. | 2016 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:40:34 GMT 2023
by
admin
on
Sat Dec 16 11:40:34 GMT 2023
|
| Record UNII |
L297UZF32G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
615571-23-8
Created by
admin on Sat Dec 16 11:40:34 GMT 2023 , Edited by admin on Sat Dec 16 11:40:34 GMT 2023
|
PRIMARY | |||
|
9954539
Created by
admin on Sat Dec 16 11:40:35 GMT 2023 , Edited by admin on Sat Dec 16 11:40:35 GMT 2023
|
PRIMARY | |||
|
L297UZF32G
Created by
admin on Sat Dec 16 11:40:35 GMT 2023 , Edited by admin on Sat Dec 16 11:40:35 GMT 2023
|
PRIMARY | |||
|
300000042454
Created by
admin on Sat Dec 16 11:40:35 GMT 2023 , Edited by admin on Sat Dec 16 11:40:35 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
We examined the effect of GlyT1 inhibitor SSR-504734 on cognitive flexibility assessed in the attentional set-shifting task in rats (ASST). The second goal was to elucidate whether SSR-504734 effect has been due to the compound's action at glycine/NMDAR site. Rats treated with SSR-504734 (3 and 10 mg/kg, IP) required significantly less trials to criteria during extra-dimensional shift (EDs) phase of the ASST. The effect of SSR-504734 (3 mg/kg) was completely prevented by the glycine/NMDAR site antagonist, L-687,414 (30 mg/kg, IP) that by itself exerted no effect on cognitive flexibility. It is suggested that GlyT1 inhibitors like SSR-504734 may represent a useful pharmacological approach for cognitive enhancement, especially in domains critically affected in schizophrenia.
|
||
|
ACTIVE MOIETY |
Class: Antipsychotic; Mechanism of Action: Glycine transporter 1 inhibitor; Highest Development Phase: Discontinued for Schizophrenia
|
||
|
ACTIVE MOIETY |
Adult rats spent more time exploring the novel than the familiar juvenile. This capacity for social novelty discrimination was impaired in rats that received neonatal PCP treatment and the impaired discrimination could be reversed by acute treatment with antipsychotic drugs such as clozapine (0.3-3 mg/kg) and the glycine transporter GlyT1 inhibitor SSR-504734 (1-10 mg/kg).
|